Advantages and features of oral administration of daprodustat

Daprodustat (Daprodustat), as a HIF-PHI oral drug that attracts global attention, has significant advantages in the treatment of chronic kidney disease anemia, and its most critical differentiated value is the treatment convenience and physiological regulation advantages brought by its "oral administration". As the number of CKD patients continues to grow, how to manage anemia in a simpler and more appropriate way has become a clinical focus, which has also made daprostat one of the most popular drugs in the field of kidney disease in recent years.

The primary advantage of oral administration is improved patient compliance. The treatment model of long-term dependence on ESA injectable preparations is not friendly to many CKD patients, especially elderly patients, people with limited mobility or those who live far from hospitals. Daprostat can be treated by taking it orally every day, which greatly reduces the number of patients' trips to the hospital and makes anemia management more family-based and continuous. This “home-administerable” feature is particularly important for patients with chronic diseases and also helps medical institutions reduce the pressure on injection treatments.

From the perspective of pharmacological mechanism, oral HIF-PHI drugs can better simulate the body's endogenous redness-promoting mechanism under mild hypoxia. Daprostat inhibits HIF-PHD, increases HIF levels, stimulates endogenous erythropoietin production, and promotes iron absorption and mobilization. This "regulation from the source" method is different from the traditional ESA which directly supplements hemoglobin, so the hemoglobin changes more smoothly and is close to the physiological pattern, which reduces the potential risks caused by the rapid rise of hemoglobin and also improves the problem of insufficient response of some patients to ESA .

Another advantage is the iron metabolism regulating effect. CKD Patients with CKD are often accompanied by problems such as iron utilization disorders and increased inflammatory status. Daprostat can promote the release of iron from storage stores, increase functional iron levels, and make the hematopoietic process smoother. For patients who cannot tolerate intravenous iron therapy or have poor iron absorption, oral HIF-PHI provides a new approach.

References: https://en.wikipedia.org/wiki/Daprodustat